Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.

Preliminary webcast agenda:

Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults

Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults

Update on the Prepare™ trial for Infants via Maternal Immunization

Conference call details are as follows:

Conference call and webcast replay:

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Andrea N. Flynn, Ph.D.

Director, Investor Relations

SOURCE Novavax, Inc.

more press release views with